In the last few years, advances in pharmacotherapy and immunotherapy have given new hope in CRPC, with increases in overall survival. Advanced practice providers and nurses need to have an understanding of these treatments, in what setting they are used, side effects, monitoring indicated, and possible complications. Discussion on how to manage advanced prostate cancer and establish a specialized clinic in your practice, and how to monitor current treatments is presented.
Contact hours available until 11/7/18.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Planning Committee Disclosures:
• Valre Welch, MSN, RN, CPNP - Consultant: Hollister Clinical Advisory Board
• Gina Powley, MSN, ANP-BC - Speakers Bureau: Astellas and Medivation
Speaker Disclosures:
• Leanne Schimke, MSN, FNP-C, CRNP, CUNP - Speakers Bureau: Bayer Xofigo
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Learning Outcome:
At the conclusion of this session, the participants will be able to critically assess evidence-based treatment options for castration-resistant prostate cancer, focusing on new and emerging therapies to provide comprehensive care and counsel to patients with metastatic CRPC.